JPMorgan Chase & Co’s Arcutis Biotherapeutics ARQT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $7.69M | Buy |
548,789
+5,407
| +1% | +$75.8K | ﹤0.01% | 2394 |
|
|
2025
Q1 | $8.5M | Sell |
543,382
-598,123
| -52% | -$9.35M | ﹤0.01% | 2297 |
|
|
2024
Q4 | $15.9M | Sell |
1,141,505
-155,406
| -12% | -$2.16M | ﹤0.01% | 1900 |
|
|
2024
Q3 | $12.1M | Buy |
1,296,911
+11,833
| +0.9% | +$110K | ﹤0.01% | 2047 |
|
|
2024
Q2 | $12M | Buy |
1,285,078
+284,872
| +28% | +$2.65M | ﹤0.01% | 1988 |
|
|
2024
Q1 | $9.91M | Buy |
1,000,206
+928,741
| +1,300% | +$9.2M | ﹤0.01% | 2130 |
|
|
2023
Q4 | $231K | Sell |
71,465
-7,246
| -9% | -$23.4K | ﹤0.01% | 4370 |
|
|
2023
Q3 | $418K | Buy |
78,711
+7,703
| +11% | +$40.9K | ﹤0.01% | 3816 |
|
|
2023
Q2 | $677K | Buy |
71,008
+15,969
| +29% | +$152K | ﹤0.01% | 3628 |
|
|
2023
Q1 | $605K | Buy |
55,039
+10,431
| +23% | +$115K | ﹤0.01% | 3719 |
|
|
2022
Q4 | $660K | Buy |
44,608
+1,062
| +2% | +$15.7K | ﹤0.01% | 3608 |
|
|
2022
Q3 | $833K | Buy |
43,546
+10,434
| +32% | +$200K | ﹤0.01% | 3474 |
|
|
2022
Q2 | $706K | Buy |
33,112
+6,090
| +23% | +$130K | ﹤0.01% | 3683 |
|
|
2022
Q1 | $520K | Buy |
27,022
+4,646
| +21% | +$89.4K | ﹤0.01% | 3971 |
|
|
2021
Q4 | $464K | Buy |
22,376
+2,080
| +10% | +$43.1K | ﹤0.01% | 4116 |
|
|
2021
Q3 | $484K | Buy |
20,296
+862
| +4% | +$20.6K | ﹤0.01% | 3984 |
|
|
2021
Q2 | $531K | Buy |
19,434
+4,582
| +31% | +$125K | ﹤0.01% | 3954 |
|
|
2021
Q1 | $430K | Buy |
14,852
+5,527
| +59% | +$160K | ﹤0.01% | 4119 |
|
|
2020
Q4 | $262K | Buy |
9,325
+2,586
| +38% | +$72.7K | ﹤0.01% | 4063 |
|
|
2020
Q3 | $209K | Buy |
6,739
+3,540
| +111% | +$110K | ﹤0.01% | 3717 |
|
|
2020
Q2 | $96K | Sell |
3,199
-152
| -5% | -$4.56K | ﹤0.01% | 3978 |
|
|
2020
Q1 | $100K | Buy |
+3,351
| New | +$100K | ﹤0.01% | 3934 |
|